Zhang Y, Yang J, Ding M, Li L, Lu Z, Zhang Q, et al. Tumor-penetration and antitumor efficacy of cetuximab are enhanced by co-administered iRGD in a murine model of human NSCLC. Oncol Lett. 2016;12:3241-3249 pubmed

Kimani S, Kumar S, Davra V, Chang Y, Kasikara C, Geng K, et al. Normalization of TAM post-receptor signaling reveals a cell invasive signature for Axl tyrosine kinase. Cell Commun Signal. 2016;14:19 pubmed publisher

Lakschevitz F, Hassanpour S, Rubin A, Fine N, Sun C, Glogauer M. Identification of neutrophil surface marker changes in health and inflammation using high-throughput screening flow cytometry. Exp Cell Res. 2016;342:200-9 pubmed publisher

Vergani E, Di Guardo L, Dugo M, Rigoletto S, Tragni G, Ruggeri R, et al. Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b. Oncotarget. 2016;7:4428-41 pubmed publisher

Carpenter E, Rader J, Ruden J, Rappaport E, Hunter K, Hallberg P, et al. Dielectrophoretic capture and genetic analysis of single neuroblastoma tumor cells. Front Oncol. 2014;4:201 pubmed publisher

Setúbal Destro Rodrigues M, Gammon L, Rahman M, Biddle A, Nunes F, Mackenzie I. Effects of Cetuximab and Erlotinib on the behaviour of cancer stem cells in head and neck squamous cell carcinoma. Oncotarget. 2018;9:13488-13500 pubmed publisher

Burga L, Hu H, Juvekar A, Tung N, Troyan S, Hofstatter E, et al. Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice. Breast Cancer Res. 2011;13:R30 pubmed publisher

He Y, Yuan X, Lei P, Wu S, Xing W, Lan X, et al. The antiproliferative effects of somatostatin receptor subtype 2 in breast cancer cells. Acta Pharmacol Sin. 2009;30:1053-9 pubmed publisher